ERAL1 and breast neoplasm: Consistent with such HYAL1 increase, low molecular weight products of hyaluronan breakdown were enhanced in aggressive breast tumors and ERα-negative cell lines, providing these fragments with a potential clinical value for breast cancer metastasis [58].